News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,656 Results
Type
Article (14899)
Company Profile (299)
Press Release (266452)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79835)
Career Advice (162)
Deals (13337)
Drug Delivery (39)
Drug Development (50700)
Employer Resources (31)
FDA (5836)
Job Trends (5167)
News (145076)
Policy (10071)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (81)
Alliances (21761)
ALS (125)
Alzheimer's disease (1032)
Antibody-drug conjugate (ADC) (242)
Approvals (6031)
Artificial intelligence (261)
Autoimmune disease (114)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (100)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (45)
Breast cancer (345)
Cancer (3137)
Cardiovascular disease (237)
Career advice (147)
Career pathing (7)
CAR-T (220)
CDC (5)
Cell therapy (566)
Cervical cancer (14)
Clinical research (43678)
Collaboration (1154)
Company closure (2)
Compensation (597)
Complete response letters (39)
COVID-19 (1100)
CRISPR (86)
C-suite (553)
Cystic fibrosis (112)
Data (4330)
Denatured (15)
Depression (93)
Diabetes (255)
Diagnostics (1380)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (192)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (216)
Earnings (31647)
Editorial (25)
Employer branding (4)
Employer resources (29)
Events (51675)
Executive appointments (622)
FDA (7592)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (989)
Gene editing (182)
Generative AI (22)
Gene therapy (491)
GLP-1 (504)
Government (1147)
Grass and pollen (3)
Guidances (166)
Healthcare (6611)
HIV (18)
Huntington's disease (43)
IgA nephropathy (74)
Immunology and inflammation (190)
Immuno-oncology (42)
Indications (66)
Infectious disease (1205)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (166)
Interviews (18)
IPO (7346)
IRA (12)
Job creations (867)
Job search strategy (129)
JPM (40)
Kidney cancer (9)
Labor market (22)
Layoffs (243)
Leadership (9)
Legal (1400)
Liver cancer (41)
Longevity (11)
Lung cancer (423)
Lymphoma (250)
Machine learning (24)
Management (7)
Manufacturing (376)
MASH (130)
Medical device (2662)
Medtech (2671)
Mergers & acquisitions (6618)
Metabolic disorders (725)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1957)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (865)
Now hiring (30)
Obesity (329)
Opinion (125)
Ovarian cancer (132)
Pain (102)
Pancreatic cancer (161)
Parkinson's disease (232)
Partnered (12)
Patents (301)
Patient recruitment (333)
Peanut (43)
People (26661)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15478)
Phase 2 (20293)
Phase 3 (12822)
Pipeline (3278)
Policy (90)
Postmarket research (853)
Preclinical (6535)
Press Release (30)
Prostate cancer (145)
Psychedelics (50)
Radiopharmaceuticals (238)
Rare diseases (653)
Real estate (1448)
Recruiting (12)
Regulatory (9900)
Reports (19)
Research institute (971)
Resumes & cover letters (18)
Rett syndrome (24)
RNA editing (21)
RSV (16)
Schizophrenia (123)
Series A (183)
Series B (140)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2005)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (334)
Venture capital (69)
Weight loss (173)
Women's health (26)
Worklife (2)
Date
Today (64)
Last 7 days (339)
Last 30 days (1208)
Last 365 days (17873)
2026 (1745)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18258)
Australia (3111)
California (7087)
Canada (1841)
China (775)
Colorado (248)
Connecticut (252)
Delaware (235)
Europe (39180)
Florida (904)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (395)
India (36)
Indiana (161)
Iowa (8)
Japan (225)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (736)
Massachusetts (5598)
Michigan (110)
Minnesota (247)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (32)
New Hampshire (21)
New Jersey (1649)
New Mexico (13)
New York (1764)
North Carolina (829)
North Dakota (6)
Northern California (3482)
Ohio (179)
Oklahoma (11)
Oregon (24)
Pennsylvania (1280)
Puerto Rico (9)
Rhode Island (25)
South America (215)
South Carolina (9)
Southern California (2811)
Tennessee (40)
Texas (909)
United States (23380)
Utah (97)
Virginia (136)
Washington D.C. (37)
Washington State (592)
West Virginia (1)
Wisconsin (46)
281,656 Results for "iterion therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Iterion Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of Tegavivint in Patients with Advanced Hepatocellular Carcinoma Who Have Failed One or More Systemic Treatments
Iterion Therapeutics announced it is actively enrolling a Phase 1b/2a clinical trial of its lead molecule, tegavivint, in patients with advanced hepatocellular carcinoma that have failed at least one line of systemic therapy.
February 20, 2024
·
4 min read
Drug Development
Iterion Therapeutics Announces the Initiation of a Phase 1 Clinical Trial for Tegavivint in Patients with c-Myc-overexpressing Relapsed or Refractory Large B-Cell Lymphomas
Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas.
May 16, 2023
·
4 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Drug Development
Iterion Therapeutics Announces Results from Preclinical Study of Tegavivint in Beta-Catenin Mutant Hepatocellular Carcinoma to be Presented at the 34th EORTC-NCI-AACR Symposium 2022
Iterion Therapeutics, Inc. announced that results from a preclinical murine study of tegavivint in beta-catenin activated hepatocellular carcinoma (HCC) will be featured in a poster presentation and discussion session at the 34th European Organisation for Research and Treatment of Cancer.
October 18, 2022
·
5 min read
Business
Iterion Therapeutics Hires Jean Chang as Chief Operating Officer
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the appointment of Jean Chang to the position of Chief Operating Officer.
July 14, 2021
·
4 min read
Lone Star Bio
Iterion Therapeutics Announces Presentation of Three Posters Involving Research into Tegavivint at the AACR 2022 Annual Meeting
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that three posters involving research into tegavivint will be presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting, including initial results from a Phase 1 study of tegavivint in patients with desmoid sarcomas.
April 8, 2022
·
6 min read
Drug Development
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Acute Myeloid Leukemia
Iterion Therapeutics, Inc. today announced the initiation of a Phase 1 clinical trial to investigate tegavivint as a potential treatment for acute myeloid leukemia (AML).
October 19, 2021
·
3 min read
Drug Development
Iterion Therapeutics Announces Initiation of Phase 1 Clinical Trial to Study Tegavivint in Combination with Osimertinib in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Iterion Therapeutics, Inc., a venture-backed, clinical-stage
December 9, 2021
·
5 min read
Lone Star Bio
Iterion Therapeutics Announces Results from Phase 1 Dose Escalation Study of Tegavivint in Desmoid Tumors to be Presented at the 2022 ASCO Annual Meeting
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced that results from a Phase 1 study of tegavivint in patients with desmoid tumors will be featured in a poster presentation and discussion session at the 2022 American Society of Clinical Oncology Annual Meeting (ASCO 2022). ASCO 2022 is being held June 3-7, 2022, in Chicago, Illinois.
June 1, 2022
·
4 min read
Drug Development
Iterion Therapeutics Announces Initiation of Phase 1/2 Clinical Trial to Study Tegavivint in Pediatric Cancers
Iterion Therapeutics, Inc., a venture-backed, clinical-stage biotechnology company developing novel cancer therapeutics, today announced the initiation of a Phase 1/2 clinical trial to investigate tegavivint as a potential treatment for pediatric cancers, including sarcomas, lymphomas and other solid tumors that are prevalent in pediatric populations.
November 9, 2021
·
8 min read
1 of 28,166
Next
